Advances in breast cancer treatment: the emerging role of ixabepilone

References

• American Cancer Society. Cancer Facts and Figures, 2008. American Cancer Society Inc., Atlanta, GA, USA (2008).
   Google Scholar
• American Cancer Society. Breast Cancer Facts and Figures, 2007–2008. American Cancer Society Inc., Atlanta, GA, USA (2008).
   Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Bergstralh DT, Ting JP. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat. Rev.32(3), 166–179 (2006).
   PubMed Web of Science ®Google Scholar
• HERCEPTIN® (trastuzumab) intravenous infusion, package insert. Genentech, Inc., CA, USA (2008).
   Google Scholar
• Gianni L, Munzone E, Capri G et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J. Natl Cancer Inst.87(15), 1169–1175 (1995).
   PubMed Web of Science ®Google Scholar
• Jones SE, Erban J, Overmoyer B et al. Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol.23(24), 5542–5551 (2005).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J. Clin. Oncol.17(5), 1413–1424 (1999).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med.48, 353–374 (1997).
   PubMed Web of Science ®Google Scholar
• Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst. Rev.4, CD004421 (2007).
   PubMedGoogle Scholar
• Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J. Biol. Chem.272(4), 2534–2541 (1997).
   PubMed Web of Science ®Google Scholar
• Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res.7(5), 1429–1437 (2001).
   PubMed Web of Science ®Google Scholar
• Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res.63(18), 6026–6031 (2003).
   PubMed Web of Science ®Google Scholar
• Chou TC, Zhang XG, Balog A et al. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc. Natl Acad. Sci. USA95(16), 9642–9647 (1998).
   PubMed Web of Science ®Google Scholar
• Altmann KH. Epothilone B and its analogs – a new family of anticancer agents. Mini Rev. Med. Chem.3(2), 149–158 (2003).
   PubMed Web of Science ®Google Scholar
• Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J. Clin. Oncol.22(10), 2015–2025 (2004).
   PubMed Web of Science ®Google Scholar
• Altmann KH, Wartmann M, O’Reilly T. Epothilones and related structures – a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta1470(3), M79–M91 (2000).
   PubMed Web of Science ®Google Scholar
• Pivot X, Dufresne A, Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin. Breast Cancer7(7), 543–549 (2007).
   PubMed Web of Science ®Google Scholar
• Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol.21(9), 1866–1873 (2003).
   PubMed Web of Science ®Google Scholar
• Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res.10(4), 1289–1298 (2004).
   PubMed Web of Science ®Google Scholar
• IXEMPRA® Kit (ixabepilone) for injection, package insert. Bristol-Myers Squibb NJ, USA (2009).
   Google Scholar
• Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol.23(12), 2726–2734 (2005).
   PubMed Web of Science ®Google Scholar
• Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J. Clin. Oncol.25(23), 3421–3427 (2007).
   PubMed Web of Science ®Google Scholar
• Denduluri N, Lee JJ, Walshe J et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest. New Drugs25(1), 63–67 (2007).
   PubMed Web of Science ®Google Scholar
• Roché H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol.25(23), 3415–3420 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol.25(23), 3399–3406 (2007).
   PubMed Web of Science ®Google Scholar
• Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol.25(23), 3407–3414 (2007).
   PubMed Web of Science ®Google Scholar
• Baselga J, Zambetti M, Llombart-Cussac A et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol.27(4), 526–534 (2009).
   PubMed Web of Science ®Google Scholar
• Bunnell CA, Klimovsky J, Thomas E. Final efficacy results of a Phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J. Clin. Oncol.24(18 Suppl.), (2006) (Abstract 10511).
   Google Scholar
• Bunnell C, Vahdat L, Schwartzberg L et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin. Breast Cancer8(3), 234–241 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol.25(33), 5210–5217 (2007).
   PubMed Web of Science ®Google Scholar
• Hortobagyi G, Perez E, Vrdoljak C et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized Phase III trials. Proc. Am. Soc. Clin. Oncol. (Breast Cancer Symposium) (2008) (Abstract 186).
   Google Scholar
• Thomas ES. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol.26(13), 2223 (2008).
   Google Scholar
• Conte P, Roche H, Perez E et al. Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large Phase III studies. Cancer Res.69(2 Suppl.), (2009) (Abstract 6114).
   Google Scholar
• Sève P, Dumontet C. Is class III b-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol.9(2), 168–175 (2008).
   PubMed Web of Science ®Google Scholar
• Horak CE, Lee FY, Xu L, Galbraith S, Baselga J. High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: a retrospective analysis. J. Clin. Oncol.27(15 Suppl.), (2009) (Abstract 3587).
   Google Scholar
• Rugo HS, Roche H, Thomas E et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large Phase III clinical studies. Cancer Res.69(2 Suppl.), (2009) (Abstract 3057).
   Google Scholar
• Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol.24(10), 1633–1642 (2006).
   PubMed Web of Science ®Google Scholar
• Perez E, Pivot X, Vrdoljak E, Sparano JA, Vogel C, Peck R. A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. Cancer Res.69(2 Suppl.), (2009) (Abstract 6140).
   Google Scholar
• Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncol. Nurs. Forum32(2), 305–311 (2005).
   PubMed Web of Science ®Google Scholar
• Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin. J. Oncol. Nurs.11(3), 361–376 (2007).
   PubMedGoogle Scholar
• Visovsky C, Collins A, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin. J. Oncol. Nurs.11(6), 901–913 (2007).
   Google Scholar
• Martin V. Arthralgias and myalgias. In: Cancer Symptom Management (Third Edition). Yarbro CH, Frogge MH, Goodman M (Eds.). Jones and Bartlett, MA, USA 17–24 (2003).
   Google Scholar
• Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J.14(2), 85–93 (2008).
   PubMed Web of Science ®Google Scholar
• Richardson G, Dobish R. Chemotherapy induced diarrhea. J. Oncol. Pharm. Practice13(4), 181–198 (2007).
   PubMedGoogle Scholar
• Barsevick A, Newhall T, Brown S. Management of cancer-related fatigue. Clin. J. Oncol. Nurs.12(5 Suppl.), 21–25 (2008).
   PubMed Web of Science ®Google Scholar